A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment.

Arshiya MariamGalen Miller-AtkinsKevin M PantaloneRobert S ZimmermanJohn BarnardMichael W KattanHetal S ShahHoward L McLeodAlessandro DoriaMichael J WagnerJohn B BuseAlison A Motsinger-ReifDaniel M Rotroff

Published in: Diabetes care (2021)

We found evidence of a T2D clinical group in ACCORD that benefited from intensive glycemia treatment, and membership in this group could be predicted using genetic variants. This study generates new hypotheses with implications for precision medicine in T2D and represents an important development in this landmark clinical trial warranting further investigation.

Keyphrases

type diabetes
clinical trial
cardiovascular disease
randomized controlled trial
metabolic syndrome
cancer therapy
adipose tissue
study protocol
drug delivery
open label
phase iii